Company Filing History:
Years Active: 2021
Title: The Innovative Work of Ji-Yeong Gal in Cancer Treatment
Introduction
Ji-Yeong Gal is a prominent inventor based in Yongin-si, South Korea. His contributions to the field of pharmaceuticals have garnered attention, particularly his work on an innovative quinazoline derivative that has significant potential in cancer treatment. With a strong focus on developing therapies that minimize adverse effects, Ji-Yeong stands out as a committed inventor in the medical sciences.
Latest Patents
Ji-Yeong Gal holds one patent titled “Quinazoline derivative or its salt and pharmaceutical composition comprising the same.” This invention provides a quinazoline derivative or its pharmaceutically acceptable salt, along with a process for its preparation. The pharmaceutical composition created from this compound exhibits selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit. This targeted approach is particularly beneficial for preventing or treating cancer while effectively avoiding side effects, such as lymphopenia-associated inflammatory responses.
Career Highlights
Ji-Yeong Gal is affiliated with Yuhan Corporation, a key player in the pharmaceutical industry. His research and innovative contributions at Yuhan Corporation have positioned him among leading inventors striving for advancements in healthcare solutions. His dedication to developing effective treatments showcases his professional commitment and expertise.
Collaborations
In his professional journey, Ji-Yeong has collaborated with notable coworkers, including Young-hwan Kim and Tae-Dong Han. These collaborations have allowed for the sharing of knowledge and resources, enhancing the quality and potential impact of their research efforts in the field of pharmaceutical sciences.
Conclusion
Ji-Yeong Gal is an exemplary inventor whose work holds promise for the future of cancer treatment through his innovative quinazoline derivative. His dedication, in collaboration with skilled colleagues at Yuhan Corporation, reflects the ongoing efforts to improve healthcare and tackle the challenges of cancer therapeutics. As the landscape of pharmaceuticals continues to evolve, Ji-Yeong's contributions are sure to leave a lasting impact.